Tuovinen Timo, Häkli Jani, Rytty Riikka, Krüger Johanna, Korhonen Vesa, Järvelä Matti, Helakari Heta, Kananen Janne, Nikkinen Juha, Veijola Juha, Remes Anne M, Kiviniemi Vesa
Oulu Functional NeuroImaging, Research Unit of Health Sciences and Technology, University of Oulu, Oulu, Finland.
Medical Research Center, Oulu University Hospital, The Wellbeing Services County of North Ostrobothnia, Oulu, Finland.
J Cereb Blood Flow Metab. 2024 Dec;44(12):1535-1549. doi: 10.1177/0271678X241262583. Epub 2024 Jun 19.
Overlapping symptoms between Alzheimer's disease (AD), behavioral variant of frontotemporal dementia (bvFTD), and schizophrenia (SZ) can lead to misdiagnosis and delays in appropriate treatment, especially in cases of early-onset dementia. To determine the potential of brain signal variability as a diagnostic tool, we assessed the coefficient of variation of the BOLD signal (CV) in 234 participants spanning bvFTD (n = 53), AD (n = 17), SZ (n = 23), and controls (n = 141). All underwent functional and structural MRI scans. Data unveiled a notable increase in CV in bvFTD patients across both datasets (local and international, p < 0.05), revealing an association with clinical scores (CDR and MMSE, r = 0.46 and r = -0.48, p < 0.0001). While SZ and control group demonstrated no significant differences, a comparative analysis between AD and bvFTD patients spotlighted elevated CV in the frontopolar cortices for the latter (p < 0.05). Furthermore, CV not only presented excellent diagnostic accuracy for bvFTD (AUC 0.78-0.95) but also showcased longitudinal repeatability. During a one-year follow-up, the CV levels increased by an average of 35% in the bvFTD group, compared to a 2% increase in the control group (p < 0.05). Our findings suggest that CV holds promise as a biomarker for bvFTD, offering potential for monitoring disease progression and differentiating bvFTD from AD and SZ.
阿尔茨海默病(AD)、行为变异型额颞叶痴呆(bvFTD)和精神分裂症(SZ)之间的重叠症状可能导致误诊和适当治疗的延迟,尤其是在早发性痴呆的情况下。为了确定脑信号变异性作为诊断工具的潜力,我们评估了234名参与者的血氧水平依赖信号(BOLD)变异系数(CV),这些参与者涵盖bvFTD(n = 53)、AD(n = 17)、SZ(n = 23)和对照组(n = 141)。所有人都接受了功能和结构MRI扫描。数据显示,在两个数据集(本地和国际)中,bvFTD患者的CV显著增加(p < 0.05),揭示了与临床评分(CDR和MMSE,r = 0.46和r = -0.48,p < 0.0001)的关联。虽然SZ组和对照组没有显著差异,但AD患者和bvFTD患者之间的比较分析突出了后者额极皮质中升高的CV(p < 0.05)。此外,CV不仅对bvFTD具有出色的诊断准确性(AUC 0.78 - 0.95),而且还展示了纵向可重复性。在一年的随访中,bvFTD组的CV水平平均增加了35%,而对照组增加了2%(p < 0.05)。我们的研究结果表明,CV有望成为bvFTD的生物标志物,为监测疾病进展以及区分bvFTD与AD和SZ提供了可能性。